Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2014

01-01-2014 | Original Research

No Detectable Association Between Frequency of Marijuana Use and Health or Healthcare Utilization Among Primary Care Patients Who Screen Positive for Drug Use

Authors: Daniel Fuster, MD, PhD, Debbie M. Cheng, ScD, Donald Allensworth-Davies, PhD, Tibor P. Palfai, PhD, Jeffrey H. Samet, MD, MA, MPH, Richard Saitz, MD, MPH

Published in: Journal of General Internal Medicine | Issue 1/2014

Login to get access

ABSTRACT

BACKGROUND

Marijuana is the most commonly used illicit drug, yet its impact on health and healthcare utilization has not been studied extensively.

METHODS

To assess the cross-sectional association between frequency of marijuana use and healthcare utilization (emergency department and hospitalization) and health (comorbidity, health status), we studied patients in an urban primary care clinic who reported any recent (past 3-month) drug use (marijuana, opioids, cocaine, others) on screening. Frequency of marijuana use in the past 3 months was the main independent variable [daily/ almost daily, less than daily and no use (reference group)]. Outcomes assessed were past 3-month emergency department or hospital utilization, the presence of medical comorbidity (Charlson index ≥ 1), and health status with the EuroQol. We used separate multivariable regression models adjusting for age, sex, tobacco and other substance use.

RESULTS

All 589 participants reported recent drug use: marijuana 84 % (29 % daily, 55 % less than daily), cocaine 25 %, opioid 23 %, other drugs 8 %; 58 % reported exclusive marijuana use. Frequency of marijuana use was not significantly associated with emergency department use {adjusted odds ratio [AOR] 0.67, [95 % confidence interval (CI) 0.36, 1.24] for daily; AOR 0.69 [95 % CI 0.40,1.18] for less than daily versus no use}, hospitalization [AOR 0.79 (95 % CI 0.35, 1.81) for daily; AOR 1.23 (95 % CI 0.63, 2.40) for less than daily versus no use], any comorbidity [AOR 0.62, (95 % CI 0.33, 1.18) for daily; AOR 0.67 (95 % CI 0.38, 1.17) for less than daily versus no use] or health status (adjusted mean EuroQol 69.1, 67.8 and 68.0 for daily, less than daily and none, respectively, global p = 0.78).

CONCLUSIONS

Among adults in primary care who screen positive for any recent illicit or non-medical prescription drug use, we were unable to detect an association between frequency of marijuana use and health, emergency department use, or hospital utilization.
Literature
1.
go back to reference Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ. 2010;340:c1571.PubMedCrossRef Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ. 2010;340:c1571.PubMedCrossRef
2.
go back to reference Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the united states: 1991–1992 and 2001–2002. JAMA. 2004;291(17):2114–21.PubMedCrossRef Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the united states: 1991–1992 and 2001–2002. JAMA. 2004;291(17):2114–21.PubMedCrossRef
3.
go back to reference Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the national survey of mental health and wellbeing. Drug Alcohol Depend. 2001;63(2):147–53.PubMedCrossRef Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the national survey of mental health and wellbeing. Drug Alcohol Depend. 2001;63(2):147–53.PubMedCrossRef
4.
go back to reference Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–91.PubMedCrossRef Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–91.PubMedCrossRef
7.
go back to reference Aldington S, Harwood M, Cox B, et al. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg. 2008;138(3):374–80.PubMedCentralPubMedCrossRef Aldington S, Harwood M, Cox B, et al. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg. 2008;138(3):374–80.PubMedCentralPubMedCrossRef
8.
go back to reference Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med. 2006;166(13):1359–67.PubMedCrossRef Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med. 2006;166(13):1359–67.PubMedCrossRef
10.
go back to reference Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–9.PubMedCrossRef Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–9.PubMedCrossRef
11.
go back to reference Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 2010;29(3):318–30.PubMedCrossRef Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 2010;29(3):318–30.PubMedCrossRef
12.
go back to reference Tyurina A, Krupitsky E, Cheng DM, et al. Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers? Drug Alcohol Depend. 2013. Tyurina A, Krupitsky E, Cheng DM, et al. Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers? Drug Alcohol Depend. 2013.
13.
go back to reference Arendt M, Munk-Jorgensen P, Sher L, Jensen SO. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend. 2011;114(2–3):134–9.PubMed Arendt M, Munk-Jorgensen P, Sher L, Jensen SO. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend. 2011;114(2–3):134–9.PubMed
15.
go back to reference Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61.PubMedCrossRef Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61.PubMedCrossRef
16.
go back to reference Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36(10):1447–60.PubMedCrossRef Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36(10):1447–60.PubMedCrossRef
17.
go back to reference Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.PubMedCrossRef Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.PubMedCrossRef
18.
go back to reference Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579–88.PubMedCrossRef Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579–88.PubMedCrossRef
19.
go back to reference Hall W. The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy. 2009;20(6):458–66.PubMedCrossRef Hall W. The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy. 2009;20(6):458–66.PubMedCrossRef
20.
go back to reference el-Guebaly N, Armstrong SJ, Hodgins DC. Substance abuse and the emergency room: programmatic implications. J Addict Dis. 1998;17(2):21–40.PubMedCrossRef el-Guebaly N, Armstrong SJ, Hodgins DC. Substance abuse and the emergency room: programmatic implications. J Addict Dis. 1998;17(2):21–40.PubMedCrossRef
21.
go back to reference Althaus F, Stucki S, Guyot S, et al. Characteristics of highly frequent users of a swiss academic emergency department: a retrospective consecutive case series. Eur J Emerg Med. 2013. Althaus F, Stucki S, Guyot S, et al. Characteristics of highly frequent users of a swiss academic emergency department: a retrospective consecutive case series. Eur J Emerg Med. 2013.
22.
go back to reference Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165(4):415–20.PubMedCentralPubMed Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165(4):415–20.PubMedCentralPubMed
23.
go back to reference Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcohol Clin Exp Res. 2005;29(3):389–94.PubMedCrossRef Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcohol Clin Exp Res. 2005;29(3):389–94.PubMedCrossRef
24.
go back to reference Walley AY, Paasche-Orlow M, Lee EC, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50–6.PubMedCrossRef Walley AY, Paasche-Orlow M, Lee EC, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50–6.PubMedCrossRef
25.
go back to reference Burke RE, Donze J, Schnipper JL. Contribution of psychiatric illness and substance abuse to 30-day readmission risk. J Hosp Med. 2013. Burke RE, Donze J, Schnipper JL. Contribution of psychiatric illness and substance abuse to 30-day readmission risk. J Hosp Med. 2013.
26.
go back to reference Palepu A, Horton NJ, Tibbetts N, Dukes K, Meli S, Samet JH. Substance abuse treatment and emergency department utilization among a cohort of HIV-infected persons with alcohol problems. J Subst Abuse Treat. 2003;25(1):37–42.PubMedCrossRef Palepu A, Horton NJ, Tibbetts N, Dukes K, Meli S, Samet JH. Substance abuse treatment and emergency department utilization among a cohort of HIV-infected persons with alcohol problems. J Subst Abuse Treat. 2003;25(1):37–42.PubMedCrossRef
27.
go back to reference Siegal HA, Falck RS, Wang J, Carlson RG, Massimino KP. Emergency department utilization by crack-cocaine smokers in dayton, ohio. Am J Drug Alcohol Abuse. 2006;32(1):55–68.PubMedCrossRef Siegal HA, Falck RS, Wang J, Carlson RG, Massimino KP. Emergency department utilization by crack-cocaine smokers in dayton, ohio. Am J Drug Alcohol Abuse. 2006;32(1):55–68.PubMedCrossRef
28.
go back to reference Larson MJ, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. Emergency department and hospital utilization among alcohol and drug-dependent detoxification patients without primary medical care. Am J Drug Alcohol Abuse. 2006;32(3):435–52.PubMedCrossRef Larson MJ, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. Emergency department and hospital utilization among alcohol and drug-dependent detoxification patients without primary medical care. Am J Drug Alcohol Abuse. 2006;32(3):435–52.PubMedCrossRef
29.
go back to reference French MT, Fang H, Balsa AI. Longitudinal analysis of changes in illicit drug use and health services utilization. Health Serv Res. 2011;46(3):877–99.PubMedCrossRef French MT, Fang H, Balsa AI. Longitudinal analysis of changes in illicit drug use and health services utilization. Health Serv Res. 2011;46(3):877–99.PubMedCrossRef
30.
go back to reference Marshall BD, Grafstein E, Buxton JA, et al. Frequent methamphetamine injection predicts emergency department utilization among street-involved youth. Public Health. 2012;126(1):47–53.PubMedCentralPubMedCrossRef Marshall BD, Grafstein E, Buxton JA, et al. Frequent methamphetamine injection predicts emergency department utilization among street-involved youth. Public Health. 2012;126(1):47–53.PubMedCentralPubMedCrossRef
31.
go back to reference Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1–3):280–95.PubMedCentralPubMedCrossRef Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1–3):280–95.PubMedCentralPubMedCrossRef
32.
go back to reference Kaner EF, Dickinson HO, Beyer F, et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev. 2009;28(3):301–23.PubMedCrossRef Kaner EF, Dickinson HO, Beyer F, et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev. 2009;28(3):301–23.PubMedCrossRef
33.
go back to reference Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.PubMedCrossRef Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.PubMedCrossRef
34.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
35.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.PubMedCrossRef
36.
go back to reference EuroQol--a new facility for the measurement of health-related quality of life. the EuroQol group. Health Policy. 1990;16(3):199–208. EuroQol--a new facility for the measurement of health-related quality of life. the EuroQol group. Health Policy. 1990;16(3):199–208.
37.
go back to reference Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38(1):115–21.PubMedCrossRef Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38(1):115–21.PubMedCrossRef
38.
go back to reference Mukamal KJ, Maclure M, Muller JE, Mittleman MA. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J. 2008;155(3):465–70.PubMedCentralPubMedCrossRef Mukamal KJ, Maclure M, Muller JE, Mittleman MA. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J. 2008;155(3):465–70.PubMedCentralPubMedCrossRef
39.
go back to reference Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.PubMedCrossRef Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.PubMedCrossRef
Metadata
Title
No Detectable Association Between Frequency of Marijuana Use and Health or Healthcare Utilization Among Primary Care Patients Who Screen Positive for Drug Use
Authors
Daniel Fuster, MD, PhD
Debbie M. Cheng, ScD
Donald Allensworth-Davies, PhD
Tibor P. Palfai, PhD
Jeffrey H. Samet, MD, MA, MPH
Richard Saitz, MD, MPH
Publication date
01-01-2014
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 1/2014
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2605-z

Other articles of this Issue 1/2014

Journal of General Internal Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.